Sotorasib in KRAS G12C-Mutated Metastatic Colorectal Cancer: CodeBreaK 100 Trial
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On December 14, 2021, Marwan G. Fakih and colleagues from the City of Hope Comprehensive Cancer Center published the results of the CodeBreaK 100 (NCT03600883) Phase 2 clinical trial in The Lancet Oncology. This study focused on the colorectal cancer (CRC) cohort of patients with KRAS G12C-mutated advanced solid tumors treated with Sotorasib.
Study Design: CodeBreaK 100 CRC Cohort
This open-label, multicenter Phase 2 trial enrolled 62 patients with KRAS G12C-mutated metastatic colorectal cancer who had progressed after prior standard therapies. All patients received Sotorasib at a dose of 960 mg orally once daily.
The primary endpoint was the objective response rate (ORR). Secondary endpoints included the disease control rate (DCR) and progression-free survival (PFS).
Key Efficacy Results
- Objective Response Rate (ORR): 9.7% (6 out of 62 patients).
- All six responders achieved a partial response (PR).
- Disease Control Rate (DCR): 82.3%
- Median Progression-Free Survival (PFS): 4.0 months.
While the response rate was lower than that observed in KRAS G12C-mutated non-small cell lung cancer, the high disease control rate suggests some degree of clinical activity in this challenging population.
Safety Profile
Sotorasib was generally well-tolerated:
- Grade 3 Adverse Events: Occurred in 10% of patients, with diarrhea (3%) being the most common.
- Grade 4 Adverse Events: One patient (2%) experienced elevated blood creatine phosphokinase.
- No treatment-related deaths were reported.
Conclusion
The researchers concluded that while the ORR of 9.7% did not meet the predefined target for the monotherapy cohort, Sotorasib demonstrates a manageable safety profile and evidence of disease stability in heavily pretreated KRAS G12C-mutated metastatic CRC. Current research is exploring Sotorasib in combination with other agents (such as EGFR inhibitors) to enhance its efficacy in colorectal cancer.
Source: The Lancet Oncology - CodeBreaK 100 Colorectal Cancer Results
#ColorectalCancer #KRASG12C #Sotorasib #CodeBreaK100 #PrecisionMedicine #CancerResearch
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4